Susu Zhou

Internal Medicine

725 Irving Ave
Syracuse, NY 13210

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1-negative cancers: a systematic review and meta-analysis.

Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1-negative cancers: a systematic review and meta-analysis.

Journal: Immunotherapy

Published: August 25, 2026

CLO26-075: Are PARP Inhibitors Effective Beyond Homologous Recombination Repair-Deficiency in Castration-Resistant Prostate Cancer? A Meta-Analysis.

CLO26-075: Are PARP Inhibitors Effective Beyond Homologous Recombination Repair-Deficiency in Castration-Resistant Prostate Cancer? A Meta-Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 30, 2026

CLO26-075: Are PARP Inhibitors Effective Beyond Homologous Recombination Repair-Deficiency in Castration-Resistant Prostate Cancer? A Meta-Analysis.

CLO26-075: Are PARP Inhibitors Effective Beyond Homologous Recombination Repair-Deficiency in Castration-Resistant Prostate Cancer? A Meta-Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.

Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.

Journal: Clinical genitourinary cancer

Published: March 09, 2026

Can PARP Inhibitors Benefit Patients with Homologous Recombination Repair-Proficient Castration-Resistant Prostate Cancer? A Meta-analysis.

Can PARP Inhibitors Benefit Patients with Homologous Recombination Repair-Proficient Castration-Resistant Prostate Cancer? A Meta-analysis.

Journal: Targeted oncology

Published: August 19, 2025

Do Older Patients With Metastatic Hormone-Sensitive Prostate Cancer Benefit From Triplet or Doublet Therapy? A Network Meta-Analysis.

Do Older Patients With Metastatic Hormone-Sensitive Prostate Cancer Benefit From Triplet or Doublet Therapy? A Network Meta-Analysis.

Journal: Clinical genitourinary cancer

Published: February 09, 2025

A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions.

A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions.

Journal: Cancers

Published: November 25, 2024

Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis.

Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis.

Journal: Targeted oncology

Published: May 14, 2024

Letter to the Editor regarding the article "A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: How to choose drugs appropriately?"

Letter to the Editor regarding the article "A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: How to choose drugs appropriately?"

Journal: Critical reviews in oncology/hematology

Published: March 21, 2024

Endocrine adverse events in patients with cancer receiving perioperative immune checkpoint blockade: a meta-analysis of randomized controlled trials.

Endocrine adverse events in patients with cancer receiving perioperative immune checkpoint blockade: a meta-analysis of randomized controlled trials.

Journal: Therapeutic advances in medical oncology

Published: February 17, 2024

Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.

Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.

Journal: Clinical genitourinary cancer

Published: December 06, 2023

Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials.

Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials.

Journal: The Lancet. Oncology

Published: July 05, 2023

Showing 1-12 of 13

Last Updated: 09/26/2026